BrainsWay Ltd. (BRSYF)
Stock analysis · OTC · Healthcare · Medical - Specialties
BrainsWay Ltd. (BRSYF) is a publicly traded company in the Healthcare sector. Latest price: $11.00. Market cap $442.78M. Trailing PE 46.75. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.
Get full analysis → Short-Term Analysis →1-Year Price
Earnings
Proprietary Signals
About BrainsWay Ltd.
BrainsWay Ltd. is a global medical technology company focused on innovating and providing non-invasive neurostimulation therapies for a broad spectrum of mental health and neurological conditions. Operating across the United States, Europe, Israel, and other international markets, the company's core offering is its Deep Transcranial Magnetic Stimulation (dTMS) platform. This advanced technology is employed in the treatment of numerous disorders, including severe depression, anxious depression, obsessive-compulsive disorder, smoking addiction, bipolar disorders, post-traumatic stress disorder, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post-stroke rehabilitation, and Parkinson's disease. BrainsWay's solutions are primarily adopted by psychiatrists, hospitals, and specialized medical centers. The company was established in 2003 and has its headquarters situated in Jerusalem, Israel.
Valuation
| P/E (TTM) | 46.75× |
|---|---|
| P/S (TTM) | 7.03× |
| P/B | 5.73× |
| PEG | 0.78× |
| P/FCF (TTM) | 83.40× |
| EV / EBITDA | 58.73× |
| EV / Sales | 6.18× |
| Earnings Yield | 2.08% |
| Free Cash Flow Yield | 1.20% |
Fundamentals
| Enterprise Value | $400.58M |
|---|---|
| Revenue (TTM) | $64.77M |
| Net Income (TTM) | $9.49M |
| Free Cash Flow (TTM) | $8.01M |
| Net Debt | -$54.81M |
| Working Capital | $58.75M |
| Gross Margin | 75.33% |
| Operating Margin | 12.18% |
| Net Margin | 14.61% |
| Return on Equity | 12.69% |
| Return on Invested Capital | 7.71% |
Peers
Recent News
- No recent news available.
Related
Browse more tickers: sitemap